Download PDF
Hamostaseologie 2008; 28(S 01): S86-S89
DOI: 10.1055/s-0037-1621424
Original article
Schattauer GmbH

Antihaemophilic factor, plasma/albumin-free method experience assessed through ongoing post-authorisation safety surveillance

Erfahrungen mit der antihämophilen Faktor, plasma-/albuminfreien Methode durch laufende Überwachung der Sicherheit
H. Gajek
1   Baxter Healthcare Corp, Westlake Village, CA, USA
,
H. Luu
1   Baxter Healthcare Corp, Westlake Village, CA, USA
,
B. Ewenstein
1   Baxter Healthcare Corp, Westlake Village, CA, USA
,
A. Kriukov
1   Baxter Healthcare Corp, Westlake Village, CA, USA
,
K. Barker
1   Baxter Healthcare Corp, Westlake Village, CA, USA
,
R. Berg
1   Baxter Healthcare Corp, Westlake Village, CA, USA
,
D. Stephens
1   Baxter Healthcare Corp, Westlake Village, CA, USA
,
G. Spotts
1   Baxter Healthcare Corp, Westlake Village, CA, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
04 January 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Data on file. Baxter Healthcare Corporation.
    PubMed
  • 2 Octocog alpha (recombinant human coagulation Factor VIII produced by recombinant DNA technology in chinese hamster ovary cells). Summary of product characteristics. Vienna, Austria: Baxter AG; 2007
    Google Scholar
  • 3 Lassila R, Rothschild C, De Moerloose P. et al. on behalf of the European Haemophilia Therapy Standardization Board (EHTSB). Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disorders. Haemophilia 2005; 11: 353-359.
    CrossrefPubMedGoogle Scholar
  • 4 US Food and Drug Administration. Workshop on factor VIII inhibitors. http://www.fda.gov/cber/minutes/fctrviii112103t.htm. Accessed February 23, 2007.
    PubMedGoogle Scholar